Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT

Acute myeloid leukemia with runt-related transcription factor 1 gene mutation (RUNX1+ AML) is associated with inferior response rates and outcome after conventional chemotherapy. We performed a retrospective, registry-based analysis to elucidate the prognostic value of RUNX1 mutation after allogenei...

Descripción completa

Detalles Bibliográficos
Autores: Waidhauser, J., Labopin, M., Esteve Reyner, Jordi, Kroger, N., Cornelissen, J., Gedde Dahl, T., Gorkom, G. Van, Finke, J., Rovira Tarrats, Montserrat, Schaap, N., Petersen, E., Beelen, D., Bunjes, D., Savani, B., Schmid, C., Nagler, A., Mohty, M., Acute Leukemia Working Party of EBMT
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/219989
Acceso en línea:https://hdl.handle.net/2445/219989
Access Level:acceso abierto
Palabra clave:Leucèmia aguda
Teràpia cel·lular
Mutació (Biologia)
Acute leukemia
Cellular therapy
Mutation (Biology)
id ES_94a07c4367f7ca3d2cb1a10461d4432a
oai_identifier_str oai:diposit.ub.edu:2445/219989
network_acronym_str ES
network_name_str España
repository_id_str
spelling Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMTWaidhauser, J.Labopin, M.Esteve Reyner, JordiKroger, N.Cornelissen, J.Gedde Dahl, T.Gorkom, G. VanFinke, J.Rovira Tarrats, MontserratSchaap, N.Petersen, E.Beelen, D.Bunjes, D.Savani, B.Schmid, C.Nagler, A.Mohty, M.Acute Leukemia Working Party of EBMTLeucèmia agudaTeràpia cel·lularMutació (Biologia)Acute leukemiaCellular therapyMutation (Biology)Acute myeloid leukemia with runt-related transcription factor 1 gene mutation (RUNX1+ AML) is associated with inferior response rates and outcome after conventional chemotherapy. We performed a retrospective, registry-based analysis to elucidate the prognostic value of RUNX1 mutation after allogeneic stem cell transplantation (alloSCT). All consecutive adults undergoing alloSCT for AML in first complete remission (CR1) between 2013 and 2019 with complete information on conventional cytogenetics and RUNX1 mutational status were included. Endpoints of interest were cumulative relapse incidence, non-relapse mortality, overall and leukemia-free survival (OS/LFS), and GvHD-free/relapse-free survival. A total of 674 patients (183 RUNX1+, 491 RUNX1-) were identified, with >85% presenting as de novo AML. Median follow-up was 16.4 (RUNX1+) and 21.9 (RUNX1-) months. Survival rates showed no difference between RUNX1+ and RUNX1- patients either in univariate or multivariate analysis (2-year OS: 67.7 vs. 66.1%, p?=?0.7; 2-year LFS: 61.1 vs. 60.8%, p?=?0.62). Multivariate analysis identified age, donor type and poor cytogenetics as risk factors for inferior outcome. Among patients with RUNX+ AML, older age, reduced intensity conditioning and minimal residual disease at alloSCT predicted inferior outcome. Our data provide evidence that the negative influence of RUNX1 mutations in patients with AML can be overcome by transplantation in CR1.Springer Nature2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/219989Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.1038/s41409-021-01322-wBone Marrow Transplantation, 2021, vol. 56, p. 2445-2453https://doi.org/10.1038/s41409-021-01322-wcc-by (c) Waidhauser, J. et al., 2021http://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/2199892026-05-27T06:46:51Z
dc.title.none.fl_str_mv Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT
title Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT
spellingShingle Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT
Waidhauser, J.
Leucèmia aguda
Teràpia cel·lular
Mutació (Biologia)
Acute leukemia
Cellular therapy
Mutation (Biology)
title_short Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT
title_full Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT
title_fullStr Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT
title_full_unstemmed Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT
title_sort Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT
dc.creator.none.fl_str_mv Waidhauser, J.
Labopin, M.
Esteve Reyner, Jordi
Kroger, N.
Cornelissen, J.
Gedde Dahl, T.
Gorkom, G. Van
Finke, J.
Rovira Tarrats, Montserrat
Schaap, N.
Petersen, E.
Beelen, D.
Bunjes, D.
Savani, B.
Schmid, C.
Nagler, A.
Mohty, M.
Acute Leukemia Working Party of EBMT
author Waidhauser, J.
author_facet Waidhauser, J.
Labopin, M.
Esteve Reyner, Jordi
Kroger, N.
Cornelissen, J.
Gedde Dahl, T.
Gorkom, G. Van
Finke, J.
Rovira Tarrats, Montserrat
Schaap, N.
Petersen, E.
Beelen, D.
Bunjes, D.
Savani, B.
Schmid, C.
Nagler, A.
Mohty, M.
Acute Leukemia Working Party of EBMT
author_role author
author2 Labopin, M.
Esteve Reyner, Jordi
Kroger, N.
Cornelissen, J.
Gedde Dahl, T.
Gorkom, G. Van
Finke, J.
Rovira Tarrats, Montserrat
Schaap, N.
Petersen, E.
Beelen, D.
Bunjes, D.
Savani, B.
Schmid, C.
Nagler, A.
Mohty, M.
Acute Leukemia Working Party of EBMT
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Leucèmia aguda
Teràpia cel·lular
Mutació (Biologia)
Acute leukemia
Cellular therapy
Mutation (Biology)
topic Leucèmia aguda
Teràpia cel·lular
Mutació (Biologia)
Acute leukemia
Cellular therapy
Mutation (Biology)
description Acute myeloid leukemia with runt-related transcription factor 1 gene mutation (RUNX1+ AML) is associated with inferior response rates and outcome after conventional chemotherapy. We performed a retrospective, registry-based analysis to elucidate the prognostic value of RUNX1 mutation after allogeneic stem cell transplantation (alloSCT). All consecutive adults undergoing alloSCT for AML in first complete remission (CR1) between 2013 and 2019 with complete information on conventional cytogenetics and RUNX1 mutational status were included. Endpoints of interest were cumulative relapse incidence, non-relapse mortality, overall and leukemia-free survival (OS/LFS), and GvHD-free/relapse-free survival. A total of 674 patients (183 RUNX1+, 491 RUNX1-) were identified, with >85% presenting as de novo AML. Median follow-up was 16.4 (RUNX1+) and 21.9 (RUNX1-) months. Survival rates showed no difference between RUNX1+ and RUNX1- patients either in univariate or multivariate analysis (2-year OS: 67.7 vs. 66.1%, p?=?0.7; 2-year LFS: 61.1 vs. 60.8%, p?=?0.62). Multivariate analysis identified age, donor type and poor cytogenetics as risk factors for inferior outcome. Among patients with RUNX+ AML, older age, reduced intensity conditioning and minimal residual disease at alloSCT predicted inferior outcome. Our data provide evidence that the negative influence of RUNX1 mutations in patients with AML can be overcome by transplantation in CR1.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/219989
url https://hdl.handle.net/2445/219989
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1038/s41409-021-01322-w
Bone Marrow Transplantation, 2021, vol. 56, p. 2445-2453
https://doi.org/10.1038/s41409-021-01322-w
dc.rights.none.fl_str_mv cc-by (c) Waidhauser, J. et al., 2021
http://creativecommons.org/licenses/by/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) Waidhauser, J. et al., 2021
http://creativecommons.org/licenses/by/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer Nature
publisher.none.fl_str_mv Springer Nature
dc.source.none.fl_str_mv Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869413709547307008
score 15,811543

Similares en LA Referencia